Zentalis Pharmaceuticals (ZNTL) Intangibles (2019 - 2021)

Zentalis Pharmaceuticals has reported Intangibles for 3 years, with the latest figure at $8.8 million in Q2 2021.

• For the quarter ending Q2 2021, Intangibles changed 0.0% year-over-year to $8.8 million; the trailing twelve-month figure through Jun 2021 stood at $8.8 million (changed 0.0% YoY), and the FY2020 full-year result was $8.8 million, changed 0.0% from the prior year.
• Intangibles for Q2 2021 stood at $8.8 million, roughly flat from $8.8 million in the prior quarter.
• The five-year high for Intangibles was $8.8 million in Q4 2019, with the low at $8.8 million in Q4 2019.
• Average Intangibles over 3 years is $8.8 million, with a median of $8.8 million recorded in 2019.
• Peak annual rise in Intangibles reached 0.0% in 2020, while the deepest fall reached 0.0% in 2020.
• Tracing ZNTL's Intangibles over 3 years: stood at $8.8 million in 2019, then changed by 0.0% to $8.8 million in 2020, then changed by 0.0% to $8.8 million in 2021.
• The last three Intangibles figures came in at $8.8 million (Q2 2021), $8.8 million (Q1 2021), and $8.8 million (Q4 2020), per Business Quant data.

Peer Comparison